The Venous Thrombus Extraction (VETEX) Clinical Study: A Preliminary Investigation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-13

Study Completion Date

2021-05-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open label, prospective, non-randomised, multi-centre first-in-human evaluation of the Vetex Thrombectomy Device for treatment of acute iliofemoral deep vein thrombosis (DVT)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients

NCT05347550

Venous Thromboembolism

RECRUITING NA

Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism

NCT03044574

Venous Thromboembolism Venous Thrombosis

COMPLETED NA

Venous Occlusion and Limb Swelling

NCT02241343

Venous Occlusion

TERMINATED NA

New Compression Hosiery Versus Standard Class II Compression Stockings After Endothermal Ablation

NCT03477227

Varicose Veins Vascular Diseases

COMPLETED NA

Vasculaire Compression System Increases Flow Velocity in the Femoral Vein

NCT01240330

Venous Thrombosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Deep Vein Thrombosis Leg

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention using the ReVene Thrombectomy Catheter

Open label, prospective, non-randomised, multi-centre first-in-human evaluation of the Vetex ReVene Thrombectomy Catheter for treatment of acute iliofemoral deep vein thrombosis (DVT).

Group Type EXPERIMENTAL

ReVene Thrombectomy Catheter

Intervention Type DEVICE

Endovascular treatment of an acute iliofemoral DVT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ReVene Thrombectomy Catheter

Endovascular treatment of an acute iliofemoral DVT

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women over 18 years of age
2. Unilateral Iliofemoral DVT
3. Patients with acute iliofemoral DVT confirmed by imaging Colour Doppler Ultrasonography (CDUS) and Magnetic Resonance Venography (MRV) or CT Venography (CTV) with symptom duration not exceeding 14 days at presentation
4. Voluntary written consent, given before performance of any clinical investigation-related procedure not part of standard medical care, and with the understanding that consent may be withdrawn at any time without prejudice to future medical care.
5. Female subjects must also meet any one of the following criteria:

1. Surgically sterile with bilateral tubal ligation or hysterectomy
2. Post-menopausal for at least one year
3. If of child-bearing potential, a pregnancy test should be performed and they should be practicing an acceptable method of birth control for the duration of the clinical investigation as judged by the Investigator, such as condoms, foams, jellies, diaphragm, intrauterine device or abstinence.
6. Subjects willing to undergo pre-and post-clinical investigation blood and urine investigations.
7. Good Functional Status as determined by the physician

Exclusion Criteria

1. Age less than 18 years
2. Symptom duration \> 14 days for the DVT episode in the index leg (i.e., non-acute DVT)
3. Inferior Vena Cava (IVC) Atresia
4. Previously stented in treatment vein
5. Patients with Antiphospholipid Syndrome
6. In the index leg: established Post-Thrombotic Syndrome (PTS)
7. Bilateral disease
8. Limb-threatening circulatory compromise
9. Known symptomatic Pulmonary Embolism
10. Hemodynamically compromised (i.e., hypotension).
11. Patients with severe dyspnea or acute systemic illness.
12. Allergy, hypersensitivity, or thrombocytopenia from heparin, rt-PA, or iodinated contrast, except for mild-moderate contrast allergies for which steroid pre-medication can be used.
13. Hemoglobin \< 9.0 mg/dl, INR \> 1.6 before warfarin was started, or platelets \< 100,000/ml.
14. Impaired renal function (estimated glomerular filtration rate (GFR) \< 30 ml/min), defined as serum creatinine ≥133µmol/L for male and ≥125 µmol/L for female.
15. Active bleeding, recent (\< 3 months) gastrointestinal (GI) bleeding, severe liver dysfunction, bleeding diathesis.
16. Recent (\< 3 months) internal eye surgery or hemorrhagic retinopathy; recent (\< 10 days) major surgery, cataract surgery, trauma, cardiopulmonary resuscitation (CPR), obstetrical delivery, or other invasive procedure.
17. History of stroke or intracranial/intraspinal bleed, tumor, vascular malformation, aneurysm.
18. Active cancer (metastatic, progressive, or treated within the last 6 months). Exception: patients with non-melanoma primary skin cancers are eligible to participate in the study.
19. Severe hypertension on repeated readings (systolic \> 180 mmHg or diastolic \> 105 mmHg).
20. Pregnant (positive pregnancy test, women of childbearing potential must be tested).
21. Recently (\< 1 month) had thrombolysis
22. Life expectancy \< 1 year or chronic non-ambulatory status.
23. Participation in any other device study within the last year, which has not yet met the primary endpoint.
24. Patient has any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol.
25. Likely inability to comply with the protocol or cooperate fully with the investigator and site personnel.
26. Impaired liver function, defined as ALT or AST ≥2.5 times upper normal limit (UNL).
27. Clinically significant, active disease (within 12 months) of the pulmonary, gastrointestinal, neurological, genitourinary or haematological system, that in the opinion of the Investigator, may confound the results of the trial or pose additional risk to the subject following use of the Vetex Thrombectomy Device.
28. Cardiac disorder, defined as: congestive heart failure (New York Heart Association (NYHA) class III/IV), diagnosis of unstable angina pectoris, cerebral stroke and or myocardial infarction within the last 12 months or planned coronary or carotid revascularisation procedures.
29. Atrial/Ventricular Septal Defect
30. Mental incapacity, unwillingness or language barrier precluding adequate understanding of the trial procedure or cooperation with trial site personnel.
31. Known or suspected abuse of alcohol, narcotics or non-prescription drugs.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No